Article

Bromfenac sodium receives award for best new branded drug introduction of 2005

ISTA Pharmaceuticals Inc. announced that the company?s launch of bromfenac sodium ophthalmic solution 0.09% (Xibrom) received the 2005 Healthcare Distribution Management Association (HDMA) Award for the Best New Branded Pharmaceutical Product Introduction and/or Product Promotion.

Chicago-ISTA Pharmaceuticals Inc. announced that the company’s launch of bromfenac sodium ophthalmic solution 0.09% (Xibrom) received the 2005 Healthcare Distribution Management Association (HDMA) Award for the Best New Branded Pharmaceutical Product Introduction and/or Product Promotion.

The HDMA announced its Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) recently during the organization’s Annual Leadership Forum.

Bromfenac sodium is ISTA Pharmaceutical’s topical ophthalmic, non-steroidal, anti-inflammatory compound for the treatment of ocular inflammation following cataract surgery. The drug was approved by the FDA in March 2005 and was launched in the second quarter of 2005.

More information is available at ISTA Pharmaceuticals’ Booth 3375.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.